RT Journal Article
SR Electronic
T1 Reproducible <em>in vivo</em> detection of locus coeruleus pathology in Parkinson’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.23.22271356
DO 10.1101/2022.02.23.22271356
A1 Hwang, Kristy S.
A1 Langley, Jason
A1 Tripathi, Richa
A1 Hu, Xiaoping P.
A1 Huddleston, Daniel E.
YR 2022
UL http://medrxiv.org/content/early/2022/05/13/2022.02.23.22271356.abstract
AB Background Patients with Parkinson’s disease undergo a loss of melanized neurons in substantia nigra pars compacta (SNc) and locus coeruleus (LC). There are very few in vivo studies of LC pathology in Parkinson’s disease with magnetic resonance imaging (MRI). Existing studies have used varying methodologies, and reproducibility has not been established for any approach.Methods Two cohorts, discovery and validation, were recruited from the Emory Movement Disorders Clinic and scanned on two different MRI scanners. In cohort 1, imaging data from 19 controls and 22 Parkinson’s disease patients were acquired with a Siemens Trio 3 Tesla scanner using a 2D gradient echo sequence with magnetization transfer preparation pulse. Cohort 2 consisted of 33 controls and 39 Parkinson’s disease patients who were scanned on a Siemens Prisma 3 Tesla scanner with a similar imaging protocol. LC and SNc volumes were segmented in both cohorts.Results SNc volume (Cohort 1: p=0.0148; Cohort 2: p=0.0011) and LC volume (Cohort 1: p=0.0412; Cohort 2: p=0.0056) were significantly reduced in the Parkinson’s disease group as compared to controls in both cohorts.Conclusion SNc volume and LC volume were significantly reduced in Parkinson’s disease compared to controls in both cohorts. This imaging approach robustly detects Parkinson’s disease effects on these structures, indicating that it is a promising marker for neurodegenerative neuromelanin loss.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by 1K23NS105944 (Huddleston) from the National Institutes of Health/National Institute of Neurological Diseases and Stroke, Michael J. Fox Foundation grants (MJFF-010556 and MJFF-010854), and the American Parkinson's Disease Foundation Center for Advanced Research at Emory University (Huddleston).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRBs of Emory University and University of California Riverside gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors